To the Editor:
Advances in therapy for childhood cancer and the resulting improved survival over time have led to a greater focus on the long-term health of childhood cancer survivors and risks for therapy-related adverse effects [1] . Therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML) are rare yet serious complications of cytotoxic cancer therapies [2] . Studies primarily conducted in adult cancer patients have demonstrated that tMDS/AML risk varies by the type of chemotherapy, with the highest risks for certain epipodophyllotoxins, alkylating agents, and platinum compounds [2] .
The limited data available on tMDS/AML risk after childhood cancer derive primarily from case-control and cohort studies, conducted predominantly in patients treated in the 1980s [3] [4] [5] [6] and 1990s [7] . However, chemotherapy regimens for many first primary cancers have evolved since the 1990s [8, 9] . Clinical trials also have reported tMDS/ AML after childhood cancer [10] [11] [12] [13] , but most of them lack sufficient sample size to quantify rare adverse effects, such as tMDS/AML, and cannot compare risks by childhood cancer type. Two population-based studies reported increasing tAML risk after childhood cancer [14, 15] . However, those studies included a small number of cases (N = 36 and 54 cases), only included follow-up through the early 2000s, and did not evaluate risks separately for those treated with chemotherapy.
We utilized data from the US population-based cancer registries of the Surveillance, Epidemiology, and End Results (SEER) program to evaluate calendar year trends in tAML risk after chemotherapy for childhood cancer during 1975-2015 in nine registries and then to broadly investigate the current landscape of tMDS/AML risk among childhood cancer survivors during 2000-2015 within the expanded set of 17 SEER registries. The outcome for the SEER 9 analyses was restricted to tAML because MDS was not systematically reported to SEER prior to 2001. For all analyses, we included individuals who were diagnosed with a non-myeloid first primary cancer at age <20 years (Supplementary Table S1), received initial chemotherapy, and survived ≥6 months after diagnosis without developing a second cancer. The tMDS/AML cases were identified using International Classification of Diseases for Oncology, Third Edition (ICD-O-3) morphology codes, and the WHO classification of tumors of hematopoietic and lymphoid tissues.
Patients treated with initial chemotherapy were followed, beginning 6 months after the first primary cancer diagnosis until the first of second cancer diagnosis, death, loss to follow-up, or end of the study (31 December, 2015) . Standardized incidence ratios (SIRs) and the accompanying exact 95% confidence intervals (CIs) quantified the relative risk of tAML or tMDS/AML compared with the general population. We also estimated excess absolute risk [EAR = (observed-expected) × 10,000/person-years]. Multivariable Poisson regression models were constructed to test for heterogeneity in the SIRs by patient characteristics. Last, we calculated the cumulative incidence of tMDS/AML with death and diagnosis of other second primary malignancies considered as competing risks, and median overall survival following tMDS/AML diagnosis. More details on the methods can be found in supplementary materials.
Initial analyses focused on 25,933 patients who received initial chemotherapy for first primary childhood cancers diagnosed during 1975-2015 from nine SEER registries ( Supplementary Table S2 , Fig. 1 ). Analyses by calendar year revealed significantly higher tAML risks within <5 years from initial diagnosis in more recent calendar years for lymphoid (SIR < 1990 = 35; 95%CI = 10-90; SIR 1990-1999 = 53; 95%CI = 21-108; SIR 2000-2015 = 101; 95%CI = 61-157; P-trend 0.026) or solid cancers (SIR < 1990 = 47; 95%CI = 13-120; SIR 1990-1999 = 107; 95% CI = 55-187; SIR 2000-2015 = 171; 95%CI = 114-247; P-trend < 0.005). Similar but nonsignificant temporal patterns were observed for tAML risk ≥5 years after diagnosis.
Subsequent analyses focused on 36,975 childhood cancer survivors diagnosed during 2000-2015 and treated with initial chemotherapy from 17 SEER registries (Table 1) . We observed 186 tMDS/AML cases (18 tMDS, 168 tAML) compared with 2.3 MDS/AML cases expected, representing an approximately 80-fold increased risk (95%CI = 69-92) and an excess of 8.3 cases/10,000 person-years. Over half (N = 106) were diagnosed after initial chemotherapy for a solid tumor, most commonly sarcoma (N = 62, SIR = 204; 95%CI = 156-261; EAR = 22.3). Despite the absence of data on specific chemotherapy drugs in SEER, these risks are consistent with the use of cisplatin/doxorubicin-(osteo sarcoma), cyclophosphamide/ifosfamide/doxorubicin/etopo side-(Ewing sarcoma), and cyclophosphamide/doxorubicinbased (rhabdomyosarcoma) regimens as a mainstay of treatment for sarcomas [8] . Significantly elevated tMDS/ AML risks also were observed after initial chemotherapy for neuroblastoma and hepatic, CNS, and germ-cell tumors, with SIRs ranging from 46 to >100. These results are also consistent with the use of leukemogenic agents, including cyclophosphamide/doxorubicin/etoposide/cispla tin-(neuroblastoma), cisplatin/doxorubicin-(hepatic), cyclo phosphamide/cisplatin/temozolomide-(CNS), and etoposide/ cisplatin-based-(germ-cell) regimens [8] .
The remaining tMDS/AML cases (N = 80) occurred among 19,371 patients treated with initial chemotherapy for lymphoid malignancies. Elevated risks were observed after ALL (N = 58, SIR = 74; 95%CI = 56-95), particularly T-ALL (N = 14, SIR = 126; 95%CI = 69-212) vs. B-ALL (N = 38, SIR = 69; 95%CI = 49-94) (P heterogeneity = 0.047). For several decades, patients treated for childhood ALL have received combination chemotherapy including cyclophosphamide and anthracyclines [9] . Increased risks in more recent years could reflect improved ascertainment of tAML after lymphoid malignancies since the 1980s or a true increase in risk, possibly due to dose intensification for high-risk patients, which could explain the higher risks we observed for T-cell than B-cell ALL [12] . Significantly elevated risks also were observed after initial chemotherapy for Hodgkin lymphoma (N = 15, SIR = 43; 95%CI = 24-71) and other lymphoid malignancies (N = 7, SIR = 35; 95%CI = 14-71). Chemotherapy for Hodgkin lymphoma evolved in the 1980s to reduce the use of highlyleukemogenic regimens (e.g., MOPP: mechlorethamine, vincristine, procarbazine, and prednisone) in favor of less toxic ones (e.g., ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine) [9] . However, our data suggest that the elevated Fig. 1 Risk for tAML by calendar period <5 years (a) and ≥5 years (b) following diagnosis of first primary childhood cancer among ≥6-month survivors who received initial chemotherapy, 1975-2015. Confidence interval (CI); standardized incidence ratio (SIR); therapy-related acute myeloid leukemia (tAML). P-trend: Multivariable Poisson regression models adjusted through stratification for age at first primary cancer diagnosis were used to conduct a two-sided test for trend in SIRs by calendar period of first primary cancer diagnosis (modeled as an ordinal variable) using a likelihood ratio statistic, where inclusion of the log of the expected number of cases as an offset indirectly adjusts for attained age and calendar year. The model for tAML ≥5 years following diagnosis was additionally adjusted for time since first primary cancer (5-9 vs. ≥10 years). Population characteristics and SIRs are provided in Supplementary Table S2 tMDS/AML risks after Hodgkin lymphoma persist, possibly due to aggressive treatment for relapse/progressive disease. Nearly 80% of tMDS/AML cases (N = 147) occurred within the first 5 years following childhood cancer diagnosis. Of these, 100 cases occurred within the first 3 years after diagnosis ( Supplementary Table S3 ). These results are consistent with the use of topoisomerase-II inhibitors for pediatric cancers [8, 9] , which has been associated with earlier-onset leukemias compared with alkylating agents [2] . For all first primary childhood cancers combined, tMDS/AML risks were significantly higher at <5 (SIR = 119; 95%CI = 100-140) vs. ≥5 (SIR = 36; 95%CI = 26-49) years after diagnosis (P heterogeneity < 0.001). SIRs continued to decrease in the period of ≥5 years after diagnosis, but the overall SIR remained significantly elevated ≥7 years after diagnosis (N = 11, SIR = 15; 95%CI = 7-27), suggesting the effect of subsequent chemotherapy for relapsed/progressive disease.
In exploratory analyses by patient subgroup, tMDS/AML risk did not statistically significantly vary by age at diagnosis of childhood cancer ( Supplementary Table S4 ), in contrast with adult studies that report higher SIRs for individuals diagnosed at younger ages. Additional studies with detailed treatment data are needed to clarify whether risks do, indeed, vary by age at exposure. Alternatively, observed risk differences by age in adult studies may be attributed to the low baseline MDS/AML risk at younger ages in the general population or differences in treatment approaches for patients of different ages with varying comorbidities. Finally, SIRs for tMDS/AML were similar among patients who received initial chemotherapy and radiotherapy vs. initial chemotherapy without known radiotherapy ( Supplementary Table S5 ). These findings support previous literature that has suggested a weak effect, if any, of radiotherapy, beyond that from chemotherapy, on leukemia risk [7] .
Despite the strikingly elevated SIRs for tMDS/AML, the 10-year cumulative incidence of tMDS/AML following chemotherapy was generally <1% for all first primary childhood cancers, with the exception of sarcoma (10-year cumulative incidence = 1.44%; 95%CI = 1.11-1.84%) ( Supplementary  Fig. 1 ). Survival following tMDS/AML was poor (median overall survival = 16 months). High prevalence of adverse cytogenetics and suboptimal response to standard treatment approaches may adversely affect prognosis for tMDS/AML compared with de novo MDS/AML [2] . Further studies are needed to characterize the cytogenetic profiles of tMDS/AML occurring after chemotherapy for childhood cancer and to identify optimal treatment strategies.
The major limitation of our study was the lack of information in SEER on specific chemotherapeutic agents, doses and duration of initial treatment, and subsequent therapy. Receipt of initial chemotherapy is also underascertained in SEER; therefore, we could not directly compare tMDS/AML risks among childhood cancer survivors treated with and without initial chemotherapy. Future studies with detailed data on initial and subsequent courses of therapy including agents, doses, and duration are critical to identify patients at highest risk of developing tMDS/AML based on their first cancer treatment exposures and perhaps genetic susceptibility. In addition, we had insufficient sample size for our analyses of patient subgroups, which should be interpreted cautiously due to limited statistical power.
In summary, our data enabled us to examine patterns in tMDS/AML risks in a large, population-based cohort across a broad range of childhood cancer survivors with systematic long-term follow-up. We demonstrate that tAML risk after initial chemotherapy for childhood cancer increased significantly during 1975-2015 and was strikingly elevated after most common childhood cancer types during 2000-2015.
These results represent the first comprehensive assessment of the current landscape of tMDS/AML risk after chemotherapy for childhood cancer, following substantial evolution in treatment approaches for many types of childhood cancer over the last several decades [8, 9] . Due to the expansion of SEER in 2000 (~28% of the US population vs. 9-13% during 1975-1999), the increasing use of initial chemotherapy to treat certain childhood cancers more recently, and the higher tMDS/AML risks associated with current treatment approaches, our study includes a larger number of cases than previous studies of tMDS/AML after childhood cancers. Although tMDS/AML is rare, the poor prognosis underscores the importance of counseling patients and their families regarding the risks and benefits of specific treatments. Future research should be directed toward more precisely identifying susceptible individuals. leukemia in adult patients in Western countries [1] [2] [3] . NOTCH1 mutations associate with clinically aggressive forms of CLL and have emerged as an independent predictor of adverse prognosis [3] . Approximately 80% of NOTCH1 mutations in CLL consist of a 2-bp CT frameshift deletion (c.7541_7542delCT) that generates a truncation in the C-terminal PEST domain and prolongs the half-life of the active form of NOTCH1, i.e., the intracellular domain of NOTCH (ICN) [1, 2, [4] [5] [6] . There is evidence that the NOTCH1 mutation results in a truncated protein more stable than wild-type (WT) protein, thus sustaining active NOTCH1 signaling in CLL cells [4] . However, whether there is any functional difference between mutant and WT NOTCH1 remains largely unknown, and relatively little is known regarding why the most frequent NOTCH1 mutations in CLL occur in the PEST domain.
Recent studies have demonstrated that NOTCH1 mutations in CLL appear at the progenitor or pro-B cell stages [7] , and might contribute to the expansion of CLL hematopoietic progenitors or pro-B cells [8] . CLL hematopoietic progenitors display higher levels of active ICN than their healthy counterparts [9, 10] . Therefore, to investigate the functional difference between mutant and WT NOTCH1 in the B cell progenitors, we generated cell models mimicking CLL hematopoietic progenitors with high levels of ICN by ectopically expressing WT ICN (ICN) and mutant ICN (ICN-delCT) in the murine B cell progenitor Baf3 cell line [1] , and determined whether they could differentially regulate the biological characteristics of these cells. Interestingly, even though ICN-delCT was expressed at a level comparable with ICN ( Supplementary Fig. 1a ), the Baf3 cells with ICN-delCT proliferated faster than those with WT ICN in a dose-dependent manner ( Supplementary Fig. 1b ), suggesting mutant NOTCH1 may cause more expansion in pro-B cells than WT NOTCH1.
Upon entering the nucleus, ICN forms a complex with the transcription factor CSL and the Mastermind-like family of co-activators to activate the transcription of a series of downstream genes such as HES1 and DTX1 [11] . To determine whether WT and mutant ICN possess different transcriptional activities, we performed luciferase reporter assays in these cells using a 6xCSL-luciferase reporter. While both ICN and ICN-delCT significantly activated the reporter, ICN-delCT showed higher transcriptional activity than ICN (Fig. 1a ). These results indicate that the enhanced pro-B cell expansion and elevated transcriptional activity are not caused by the prolonged half-life of the active form of NOTCH1, but rather reflect a functional difference between mutant and WT NOTCH1.
To identify the mechanisms underlying the functional difference between mutant and WT NOTCH1 in pro-B cells, we sought to determine whether ICN and ICN-delCT had different associated partners in the nucleus. ICN and its associated partners were purified from nuclear extracts derived from these Baf3 cells by immunoprecipitation using NOTCH1 antibody. Mass spectrometry analysis identified protein partners of ICN ( Fig. 1b and Supplementary  Table 1 ). Interestingly, consistent with our finding that ICN-delCT showed higher transcriptional activity, we found that MTA2 and MTA1 proteins, both of which are components of the nucleosome remodeling and deacetylase (NuRD) corepressor complex [12] , co-purified with ICN but not with ICN-delCT (Supplementary Table 1 ). Factors involved in transcriptional repression, including components of the NuRD complex and the PRC1 complex, have been reported to be associated with ICN in T-cell acute lymphoblastic leukemia (T-ALL) cells [13] . However, because the primary function of ICN is to activate transcription, the biological significance of these interactions remains to be determined. To verify that the NuRD complex interacts with ICN but not ICN-delCT in B cells, we performed a coimmunoprecipitation experiment in primary cells from CLL patients and in these Baf3 cells and confirmed that ICN, but not ICN-delCT, associated with the NuRD complex components MTA2 and HDAC1 ( Fig. 1c and Supplementary Fig. 1c ). The diminished interaction between ICN-delCT and the NuRD corepressor complex might thus contribute to the elevated transcriptional activity of ICN-delCT in pro-B cells and over-activate a subset of genes critical for the survival of CLL cells, thus contributing to the pathogenesis of CLL.
Next, we asked if it was the truncation in the PEST domain that caused the diminished interaction between ICN-delCT and the NuRD complex. To this end, we examined the direct interactions between MTA2 and various PEST truncations using pull-down assays. The results showed that the truncated PEST domain from mutant NOTCH1 was no longer able to bind with MTA2, indicating the C-terminal portion of the PEST domain which is lost in mutant NOTCH1 was responsible for direct interaction with MTA2 ( Fig. 1d ). Previously, besides providing a degradation signal, other functions of the PEST domain in NOTCH1 had not yet been identified. However, our results suggest the PEST domain not only provides a degradation signal, but also participates actively in NOTCH1 function by recruiting critical protein partners such as the NuRD complex.
Because the NuRD corepressor complex interacts specifically with ICN but not with ICN-delCT in B cells, we hypothesized that at least a subset of dormant NOTCH1 target genes were not activated until NOTCH1 was mutated. To identify the NOTCH1 target genes that are preferentially activated by mutant NOTCH1, we performed gene expression profiling of these Baf3 cells. Gene ontology analysis showed that immune system processes were upregulated in Baf3 cells expressing ICN-delCT ( Supplementary Fig. 2a ).
Consistently, the KEGG pathway enrichment analysis also identified that genes referring to cytokine-cytokine receptor interaction and the chemokine signaling pathway were significantly enriched in the ICN-delCT group ( Supplementary  Fig. 2b ). In particular, genes encoding Ccl17 family chemokines, including the Ccl17 and Ccl22 genes, were significantly upregulated in the ICN-delCT group ( Fig. 2a, b ). These results indicated that the Ccl17 and Ccl22 genes as NOTCH1 target genes preferentially activated by mutant NOTCH1. In line with this, the mRNA level of CCL17 and CCL22 was significantly elevated in primary CLL cells with NOTCH1-delCT ( Fig. 2c ). We further reanalyzed the published RNA-seq data in CLL patients (GSE92626) [9] , and confirmed that the transcriptional level of the CCL17 gene was elevated in human CLL cells with NOTCH1-delCT ( Supplementary Fig. 2c, d) .
To confirmthe pivotal role of the NuRD corepressor complex in suppressing the expression of CCL17 family genes, we knocked down the MTA2 gene in the primary CLL cells and observed that MTA2 depletion significantly induced the expression of the CCL17 and CCL22 genes in NOTCH1-WT but not NOTCH1-delCT CLL cells ( Fig. 2d, e ). In contrast, the mRNA level of other NOTCH1 target genes, such as HES1, HES4, and HEY1, was not significantly induced by MTA2 depletion ( Supplementary  Fig. 3a) , indicating that only a subset of NOTCH1 target genes in CLL cells were repressed by the NuRD corepressor complex. To determine whether CCL17 gene transactivation The liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay of the protein solution immunoprecipitated using anti-NOTCH1 antibody from Baf3 cells transfected with plasmids expressing GFP-tagged ICN/ICN-delCT as indicated. The part base peak spectra of the binding targets of MTA2 are shown. c The co-IP assay of the indicated primary cells of the CLL patients. Cellular lysates were immunoprecipitated with anti-ICN (cleaved NOTCH1, Val1744) antibody (CST #4147), then immunoblotted with anti-NOTCH1 (CST #3608), anti-ICN (CST #4147), anti-MTA2, or anti-HDAC1 antibodies, respectively. CLL-WT, CLL with WT NOTCH1; CLL-delCT, CLL with NOTCH1-delCT mutation. d The GST pull-down assay to measure the interaction of MTA2 with GST tagged PEST domain (GST-324), and PEST truncated fragment (GST-N195 and GST-C129). GST-fusion proteins were purified from E. coli, evaluated by immunoblotting, and incubated with eukaryotic expressed MTA2. Glutathione beads bound proteins were evaluated by western blotting with anti-MTA2 antibody. ***P < 0.001; two-tailed t-test. Data represent means of triplicate reactions ± sem in primary CLL cells was associated with a diminished interaction between ICN-delCT and the NuRD complex, we examined the recruitment of MTA2 and HDAC1 onto the CSL-binding sites of the CCL17 gene using chromatin immunoprecipitation (ChIP) assays. Both WT ICN and ICN-delCT showed a significant enrichment on the CSL-binding sites of the CCL17 gene; however, the enrichment of MTA2 and HDAC1 on these sites was significantly decreased in NOTCH1-delCT CLL cells (Fig. 2f ). The diminished recruitment of the NuRD complex to the Ccl17 gene was also validated in ICN-delCT-expressing Baf3 cells (Supplementary Fig. 3b ). Taken together, these results suggest that the diminished interaction between ICN-delCT and the NuRD complex is responsible for the transactivation of the CCL17 gene in the NOTCH1-delCT CLL cells.
Chemokine CCL17 plays a critical role in the survival of CLL cells by modulating the tumor microenvironment [14] . Malignant CLL cells have the capacity to attract CD4 + T-cells expressing CCR4, the receptor for CCL17 and CCL22, which provide survival and growth signals to CLL cells [15] . In line with the elevated RNA level, ELISA assays also confirmed that chemokine CCL17 was significantly elevated in the serum of CLL patients with NOTCH1-delCT ( Fig. 2g ). Consistently, the chemokine Ccl17 was also significantly induced in the supernatant of ICN-delCTexpressing Baf3 cells ( Supplementary Fig. 3c ). Transwell assays further showed that the number of migrating CD4 + Tcells was notably increased by the media of ICN-delCTexpressing Baf3 cells and the serum of NOTCH1-delCT CLL patients ( Fig. 2h , i), which could be effectively blocked by CCL17 antibody. Hence, the NOTCH1 mutation in CLL is related to the induction of CCL17 and subsequently induced the migration of CD4 + T-cells, which changes the microenvironment to favor tumor cell survival. NOTCH1 genetic alterations have been described in different human malignancies, including T-ALL and CLL. Nevertheless, the reason why NOTCH1 mutations affect two different domains in CLL and T-ALL remains unclear. Our study proposes that loss of NuRD complex interaction is a novel mechanism underlying the activation of NOTCH1 prevalent in CLL ( Fig. 2j ). Our study revealed that in CLL, the prevailing NOTCH1 mutants lacking an intact C-terminal PEST domain not only became more stable, but also gained additional function by becoming more potent transcriptional activators. Our study thus explains why NOTCH1 mutations in CLL preferentially occur in the PEST domain and provides new insights that will enable more precise therapeutic strategies specific for NOTCH1mutated CLL.
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Fig. 2
The loss of NuRD interaction with mutant NOTCH1 overactivates a subset of genes critical for the survival of CLL cells. a Heatmap showing the nine upregulated genes related to the cytokine signaling pathway in ICN-delCT variants. Color indicates normalized expression level (log); Red corresponds to higher expression, and green corresponds to lower expression. b Ccl17 and Ccl22 mRNA levels in Baf3 cells transfected with the indicated plasmids. Values were normalized against Gapdh. c The transcriptional level of CCL17 and CCL22 genes in human CLL patients with WT NOTCH1 (CLL-WT, n = 18) or NOTCH1-delCT mutation (CLL-delCT, n = 7). d Primary CLL cells were infected with the indicated lentiviral vectors. Immunoblots of the indicated proteins were detected. e CCL17 and CCL22 mRNA levels in primary CLL cells described in d. Values were normalized against GAPDH. f Schematic of the CCL17 promoter indicating the CSL-binding sites (upper panel). ChIP assays detected NOTCH1-ICN, MTA2, and HDAC1 on CCL17 gene promoter performed in primary cells of the indicated CLL patients (lower panel). ChIP results are presented as the mean of experiments performed in three independent samples. g The chemokine CCL17 concentration in the serum of human CLL patients with WT NOTCH1 or NOTCH1-delCT was detected by ELISA. h The chemotaxis assay for cellular supernatants derived from Baf3 cells expressing ICN or ICN-delCT. Transwell chambers were used to detect T-cell migration ability and the number of migrated cells was counted manually. i The chemotaxis assay for the serum of human CLL patients with WT (n = 3) or NOTCH1-delCT (n = 3). j A schematic model illustrating the induction of CCL17 by NOTCH1-delCT mutation in CLL. CoA, coactivator. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant; two-tailed t-test. Data represent means of triplicate reactions ± sem To the Editor:
The World Health Organization (WHO) classification of acute myeloid leukemia (AML) has incorporated molecular genetic and cytogenetic aberrations in the definition of most entities [1] . The diagnosis of acute panmyelosis with myelofibrosis (APMF) is still not based on genomic changes but on clinicopathologic features and the exclusion of other myeloid malignancies, in particular AML with myelodysplasia-related changes (AML-MRC) [2] . APMF is a rapidly progressive hyperfibrotic subtype of "AML not otherwise specified" (AML NOS) and accounts for <1% of AML cases [3] . This aggressive disease is characterized by rapid onset of cytopenia and constitutional symptoms in the absence of splenomegaly, previous history of myeloproliferative neoplasm (MPN) or myelodysplastic These authors contributed equally: Milena Pantic, Dietmar Pfeifer syndrome (MDS), and exposure to radiation or cytotoxic drugs. Blood smears are devoid of tear-drop-shaped cells but may contain dysplastic platelets and myeloid cells including rare blasts [2, 3] . Histopathologic evaluation of core bone marrow (BM) biopsies is mandatory to recognize the hallmark of this myeloid neoplasm: "panmyelosis", i.e. trilineage myeloid proliferation with dysplastic erythropoiesis, abundant atypical megakaryocytes, and overt BM fibrosis ≥ grade 2 on a 0-3 scale and ≥20% predominantly CD34-positive precursors/blasts often arranged in clusters ( Fig. 1a-d ) [3] [4] [5] . As a consequence of dry tap BM aspiration and rare circulating CD34-positive precursors/ blasts, genetic data are reported in a limited number of patients. An abnormal karyotype lacking recurrent aberrations was identified in most APMF cases with available cytogenetic information. Published cytogenetic data were similar to AML-MRC including aberrations of chromosome 5q, 7q/7, 8, and 11q [3, 4] . Two other studies detected different chromosomal aberrations involving chromosomes 3q, 5, 12, 13q, and 22 [6, 7] . In a single APMF patient, an amplification of EVI1/MECOM within a derivative chromosome 8 was described [8] . In another study of four APMF patients no JAK2 V617F, MPL, or CALR mutations were detected [9] .
The first step of our study was to identify in our files de novo AML patients who presented with relevant fibrosis at initial diagnosis. Among those, we retrospectively reevaluated cases with available BM biopsies for the presence of clinicopathologic features consistent with the 2016 WHO criteria for APMF. Cases with a previously proven MDS-type cytogenetic profile and prominent dysplasia involving ≥ 50% at least in two lineages as mandatory for AML-MRC were excluded. In addition, no cases with megakaryocytic abnormalities, such as arrangement in dense clusters characteristic for primary myelofibrosis (PMF) were considered. By consequently applying WHO criteria, we retrieved a cohort of 16 patients that we could assign to the APMF category ( Fig. 1a-d , Table 1 , Supplementary Table 1 ). Briefly, the core biopsies showed BM fibrosis grade 2-3 associated with a generally rather low frequency of CD34-positive myeloblasts (median 30% in the total cohort), a proliferation of predominantly small dysplastic CD61-positive megakaryocytes and a macroblastic glycophorin C-positive and CD71-positive erythropoiesis with increased proerythroblasts. Using routine methods suitable for formalin-fixed paraffin-embedded (FFPE) material MPL W515L was absent in 5/5 cases, while 1/5 cases harbored a JAK2 V617F mutation with a low (5%) mutant allele burden. Karyotyping by metaphase analysis or FISH had been unsuccessful due to BM dry tap and low circulating CD34+ cells. Thus, we performed molecular studies on genomic DNA extracted from the diagnostic FFPE and EDTA-decalcified BM trephine biopsies by applying the OncoScanTM FFPE assay (Thermo Fisher Scientific, MA, USA) for whole genome tumor profiling [10] . Using stringent settings for gains and losses (Supplementary Materials and Methods) genomic copy number abnormalities (CNAs) were discovered in 94% (15/16) of APMF patients. Based on the number of CNAs we could distinguish two groups within our APMF cohort. Six patients harbored ≤ 3 (mean 2) CNAs and were referred to as low genomic complexity group (Fig. 1e , f, Table 1 , Supplementary Table 2 ). The low complexity group showed mostly single but heterogeneous CNAs (Table 1 ). In contrast, 10 patients were assigned to a high genomic complexity group since >3 (mean 15) CNAs were identified. As a part of a complex genomic profile, the most frequent CNAs were losses of 17p, 5q, and 7q (in 10, 9, and 9 patients, respectively). Other MDS-related or MPNrelated CNAs occurred with lower frequency such as loss of 18p in five patients and losses of 17q, 18q, 11p, and 3p, as well as a gain of 3q in four patients, respectively (Fig. 1e , Table 1 , Supplementary Table 2 ). The gains of chromosome 3q, 8, 12q, 17q, and 21q, as well as loss of 7q were the CNAs common to both groups and have been previously described in APMF [3, 6, 8] .
DNA for mutational analysis (Supplementary Information) was only available in 5/16 patients ( Table 1) . Three of these patients were assigned to the high complexity group while two patients were included in the low complexity group. Molecular profiling revealed TP53 mutations in all of these five patients. Taken together with the copy number results, 12/16 patients harbored TP53 abnormalities (i.e. loss of 17p and/or TP53 mutation) including 3 with inactivation of both TP53 alleles (Table 1) .
Further mutations were detected in the epigenetic regulators DNMT3A and TET2 (in 2/5 samples), signaling molecule CBL (1/5 sample), and co-repressor BCOR (in 2/5 samples). Four patients did not show TP53 abnormalities in the OncoScan assay but were not evaluable for TP53 mutation analysis. Thus, they were considered as "TP53 unknown".
As compared with other AML entities, the genetic alterations underlying APMF are not well characterized. An interesting finding that has not yet been described is the presence of TP53 aberrations in the large majority of APMF patients. In accordance, we frequently observed high levels of genomic complexity suggesting a high genomic instability universally associated with an adverse outcome in AML [11] . Patients of the large high complexity group (10/16 patients) exhibited a genetic profile overlapping with AML MRC. TP53 alterations are rare in de novo AML (about 8-14%) but are closely associated with the presence of a complex karyotype and/or monosomal karyotype [11, 12] . In a recent study, AML with TP53 mutations and chromosomal aneuploidies, such as deletions and monosomies of chromosomes 5, 7, 12, and 17, as well as trisomy 8 were considered a distinct category [12] . Patients in this subgroup were older and had the worst overall survival of all AML subgroups [11] . Accordingly, the term "AML with TP53 mutations and chromosomal aneuploidy" could also be assigned to most of our APMF patients. The detection of a JAK2 V617F mutation in one patient does not exclude de novo AML but may suggest a rapidly transformed MPN without a clinically evident chronic phase [13, 14] . MPN patients with TP53 mutations have a poor prognosis with a high risk of transformation [14] . Very high risk PMF [15] . Therefore, our results could be helpful in distinguishing APMF from PMF. Despite the molecular heterogeneity, all patients of our APMF cohort had a dismal outcome with a median survival of 5.4 months (range 1.8-11.3 months, Fig. 1g -i, Supplementary Table 1 ). No patient was treated by allogeneic hematopoietic stem cell transplantation. Three patients received standard induction chemotherapy, one patient thalidomide and another patient decitabine. Statistical analyses comparing low versus high complexity cases or those with known or unknown TP53 abnormalities did not reveal any significant differences with regard to overall survival and hematologic pretreatment parameters, except with regard to platelet counts and number of CNAs ( Fig. 1, Supplementary  Table 1 ). Patients negative for TP53 abnormalities in the OncoScan assay and unknown TP53 mutation status had significantly higher platelet counts (p = 0.045) and lower numbers of CNAs (p = 0.006) than those with TP53 abnormalities. It is worth noting that the superior survival of 11.3 months was observed in a patient of the high complexity group with a TP53 exon 10 splice site mutation receiving hypomethylating therapy (decitabine). Interestingly, the frequency of TP53 splice mutations (4/5, 80%) in our cohort is high, compared to the splice mutation frequency of around 5% in myeloid neoplasms (11/201, see Suppl.) estimated from the IARC TP53 database. Whether this observation can be confirmed and may even be linked to the fibrotic phenotype needs to be shown in a larger cohort.
The mechanisms that contribute to the typical morphologic and clinical features, and the rapidly progressive disease that entailed the designation as APMF still remain to be elucidated. Previously, we have observed an increased inflammatory T-cell rich background in APMF core biopsies [5] . Inflammatory microenvironment changes of the niche may contribute to genomic instability of hematopoietic stem cells and disease evolution. Cytokines and chemokines released from inflammatory cells and abundant megakaryocytes may contribute to the fibrotic modulation of the BM that is a hallmark of APMF. Although the number of our patients is small and the spectrum of methods that we could apply is limited, the data presented here provide further insights into the molecular basis of APMF and highlight the high prevalence of TP53 abnormalities and chromosomal aneuploidy.
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Hematopoietic stem cells (HSCs) are a rare population residing at the apex of the hematopoietic hierarchy [1] . HSCs have the capacity to self-renew and differentiate into all blood cell types, thus they play a key role in hematopoietic cell transplantation (HCT) [2] . HCT is widely used as a curative therapy for numerous malignant and nonmalignant hematological and even non-hematological diseases [3] . The fast developing field of gene editing techniques, including ZFNs, TALENs and CRISPR-Cas9, broaden usage of HCT in clinical therapy of diseases caused by genetic mutations [4] . i.e. β-thalassaemia or Sickle Cell Disease (SCD) may possibly be interrogated by CRISPR based gene editing of β-globin in HSCs from patients [5] . However, efficient gene editing and infusion of the gene edited HSC into patients requires sufficient numbers of donor HSC. In addition, when cord blood (CB) is used as the source of HSC for HCT, rare HSC numbers in single CB units may lead to delayed hematopoietic recovery in recipients [6] . It is thus important in some cases to develop efficient means that can overcome limited HSC numbers to enhance the efficacy of HCT.
Efforts are underway by many scientific groups to develop potential ways to improve engraftment of HSC. This includes mitigating EPHOSS [7] , enhancing HSC homing efficiency [8, 9] , promoting ex vivo expansion [10] [11] [12] , and by reprogramming iPS or endothelial cells to human HSC [13, 14] . However, most of these methods have not yet been adapted for clinical use, and there is still an urgent need to dissect the mechanisms behind these encouraging processes. Rigorous phenotypic analysis of HSC is an easily accessible and important method to evaluate the function of a heterogeneous cell population from bone marrow or blood samples. The rigorous phenotyping identity of human HSC identity was confirmed at a single cell level [15] . In general, freshly isolated human HSC are defined as CD34 + CD38 − CD45RA − CD90 + CD49f + . However, we still don't know if all cells in different circumstances, especially under stress conditions such as ex-vivo expansion, that are identified by CD34 + CD38 − CD45RA − CD90 + CD49f + are functional HSC with long-term repopulating capacity.
In a compound screen for agonists of human CB HSC ex vivo expansion, we found that 100 nM 12-deoxyphorbol-13-O-phenylacetate-20-acetate (DOPPA), a weak phorbol ester, significantly and greatly expands cytokine (stem cell factor (SCF), thrombopoietin (TPO), Flt-3 ligand (FL)) -stimulated phenotypic CB HSC (CD34 + CD38 − CD45RA − CD90 + CD49f + ) (Fig. 1a) . Compared with the vehicle control cultured group, the DOPPA group contains 12.4-fold more phenotypic-defined HSCs after 4-days ex vivo culture (Fig. 1b) . The phenotypic HSC number in DOPPA-treated group was~2.5 fold greater than that seen with the SR1 and UM171-treated groups at this 4-day culture time (Fig. 1b) .
We then examined the effect of DOPPA treatment on hematopoietic progenitor cells (HPCs). DOPPA significantly increased numbers of CB colony-forming unit (CFU) granulocyte/macrophage (GM), but not granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) progenitors after 4 days ex vivo culture ( Fig. 1c ), suggesting that DOPPA treatment selectively promotes ex vivo expansion of functionally recognizable granulocyte-macrophage progenitors.
In order to determine if the DOPPA expanded phenotypic HSC population had repopulating or increased repopulating capacity in vivo, we performed limiting dilution analysis to quantify SCID-repopulating cells (SRCs) by intravenous (i.v.) injection in sublethally-irradiated NOD. Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. The SRC frequency of DOPPA -cultured CB CD34 + cells and human CD45 + cell chimerism did not significantly increase compared with that of uncultured CD34 + cells and vehicle control-treated CD34 + cells ( Fig. 1d-f ; Supplementary  Table 1 ), whereas numerous studies by others, [10, 11] and ourselves (unpublished data) have shown significantly enhanced SRCs after ex-vivo expansion with SR1 and UM171. These data strongly suggest that the DOPPAexpanded phenotypically-defined HSC were not active as engrafting HSC.
Interestingly, we noticed that phenotypic HSC were significantly increased if we cultured the CD34 + cells just for 24 h with a higher concentration of DOPPA (1 μM) or other phorbol esters, including phorbol-12-myristate-13-acetate (PMA) ( Supplementary Fig. 1A, B ). We performed in vivo transplantation experiments to examine if PMA-induced phenotypic HSC have long-term engrafting capacity. 10,000 vehicle or PMA-cultured CD34 + cells were transplanted into sublethally-irradiated NSG mice. The human cell engraftment in the BM of the NSG recipients was determined 16 weeks after transplantation. Our data showed that CD34 + cells cultured with DOPPA or PMA did not engraft better than the cells cultured with vehicle control ( Supplementary  Fig. 1C, D) . To exclude the possibility that PMA might affect the homing efficiency of CD34 + cells, we did homing experiments to examine the human cell percentage engrafted into the bone marrow of the recipient NSG mice 24 h after transplantation. We found that PMA treatment did not significantly change the homing efficiency of CB HSC and HPC ( Supplementary Fig. 2A, B) . Together, these data demonstrate that the PMA-induced phenotypic HSC after ex vivo culture with cytokines were not capable of functional engraftment with long-term repopulating activity.
To understand mechanisms behind the unusual inconsistency between ex vivo HSC phenotyping analysis and in vivo functional evaluation, we did RNA-sequencing analysis to check the transcriptome of vehicle and DOPPAtreated CD34 + cells after 4 days ex-vivo culture. We noticed that expression of many genes which encode cell surface proteins including ITGA6 (CD49f) were significantly up-regulated, FDR-adjusted p-value <0.01 and the fold change (FC) >2, by DOPPA treatment (Fig. 2a ). Gene ontology (GO) analysis revealed that many GO functions related to cell surface or plasma membrane related GOs which all include ITGA6 were significantly enriched in up-regulated differentially expressed genes (DEGs) including ITGA6 after DOPPA treatment (Fig. 2b) . Quantitative PCR analysis further demonstrated that ITGA6 mRNA levels apparently increased in DOPPA-treated CD34 + HSCs and HPCs (Fig. 2c ). We also checked mRNA expression of THY1(CD90), another marker of human HSC, the signal of which was not detected by RNAseq analysis due to its low abundance. The THY1 mRNA level was largely increased in DOPPA treated CD34 + HSCs and HPCs (Fig. 2c) . Flow cytometry analysis showed that ITGA6 and THY1 surface expression was largely promoted by DOPPA ( Supplementary Fig. 2C, D) . Increased ITGA6 expression in DOPPA treated CD34 + cells was further confirmed by T-distributed Stochastic Neighbor Embedding (tSNE) analysis (Fig. 2d) . These data indicated that DOPPA We also found many genes involved in myeloid differentiation that were significantly enriched by DOPPA ( Supplementary Fig. 2E, F) numbers of CFU-GM we had detected (Fig. 1c) . These data may partly explain the DOPPA treatment-induced expansion of CFU-GM. Phenotypic analysis of HSCs is a widely used approach to relatively quickly sort or quantify numbers of HSC, allowing for a rapid read-out of these cells. However, not all published studies have focused on the correlation between the phenotyping and reconstituting capacity of the cells. Phorbol ester short treatment significantly changed the transcription and expression of cell surface markers used to define HSC, including ITGA6 and THY1. Our findings provide an excellent example for investigators in this field that it is crucial for full analysis of effects on HSC function that engrafting studies always be performed to confirm functional activities, as phenotype may not always recapitulate function. The quantification of HSC is based on expression of several cell surface markers. In some circumstances, mRNA expression needs to be considered to exclude the possibility that the transcription of those genes encoding HSC markers were changed by the treatment. Future study will likely need to be performed to identify candidate HSC markers that can reflect the reconstituting capacity of the cells in different circumstances, especially under stress conditions. Leukemia (2019) 33:2967-2970 https://doi.org/10.1038/s41375-019-0530-9
Stem cell transplantation
Novel evidence that an alternative complement cascade pathway is involved in optimal mobilization of hematopoietic stem/progenitor cells in Nlrp3 inflammasome-dependent manner To the Editor:
The mobilization of stem cells is still not well understood, despite the fact that this process is important for understanding the response of the organism to inflammation, tissue and organ injury, and pharmacological mobilization as a clinical procedure to harvest hematopoietic stem/progenitor cells (HSPCs) for hematopoietic transplantation [1, 2] . Currently, several mediators and cells have been proposed as playing a pivotal role in this phenomenon. Specifically, evidence has accumulated that this process is orchestrated by ancient evolutionary mechanisms mediated by innate immunity. All cell types belonging to the innate immunity network (granulocytes, monocytes, and dendritic cells) as well as the complement cascade (ComC) here play a crucial role [2, 3] .
The ComC is a part of the innate immune system that defends against infections. However, evidence has accumulated that it has several other effects, including involvement in organ development, tissue regeneration, and stem cell trafficking [4] . Our group proposed that the release of HSPCs from bone marrow (BM) into peripheral blood (PB) is orchestrated by the induction of "sterile inflammation" in the BM microenvironment in response to infection, tissue/organ injury, strenuous exercise, or the administration of pro-mobilizing drugs [5, 6] , such as cytokine granulocyte colony-stimulating factor (G-CSF) or AMD3100, a small-molecule inhibitor of the chemokine receptor CXCR4. G-CSF-induced or AMD3100induced pharmacological mobilization of HSPCs is a means of obtaining these cells in the clinic for hematopoietic transplantation.
The ComC consists of zymogen proteins that become activated in a cascade-mediated manner by the (i) classical, (ii) mannan-binding lectin (MBL), or (iii) alternative pathways [4] . Our previous work demonstrated that the MBL but not the classical pathway plays a pivotal role in pharmacological mobilization with G-CSF or AMD3100 [7] . Specifically, mice deficient in the C1q protein, which initiates classical ComC activation, are good G-CSF and AMD3100 mobilizers [7, 8] , in contrast to animals that are deficient in MBL or mannan-activated serum protease 2 (MASP-1) [7] . However, since MBL-KO and MASP-1-KO mice still mobilize some HSPCs in response to G-CSF and AMD3100, here we asked whether the alternative pathway of ComC activation plays a compensatory role in this process. To address this question, we performed mobilization studies in factor B (FB)-deficient (FB-KO) mice. FB is a serine protease that is required for activation of the alternative ComC pathway. In contrast to the other two pathways, the alternative pathway is not triggered by antibodies or specific structures on the surface of microorganisms. Instead, it is activated by the spontaneous hydrolysis of C3 (the third component of the ComC and the most abundant complement protein present in blood plasma) [9] .
Furthermore, supporting the important role of innate immunity in mobilization, we recently demonstrated involvement of the Nlrp3 inflammasome complex in the induction of "sterile" inflammation in BM, which triggers the mobilization of HSPCs [10, 11] . Based on this and our previous data we become interested in a potential role of alterative pathway of ComC activation in mobilization of HSPCs. Pathogen-free, 4-6-week-old FB-deficient mice were mobilized with G-CSF (Amgen, Thousand Oaks, CA, USA) for 3 days at 100 μg/kg per day by subcutaneous injection (SC) with AMD3100 (Sigma-Aldrich, St. Louis, MO, USA) for 1 day at 5 mg/kg by intraperitoneal injection (IP). Following mobilization, we measured (i) the total number of white blood cells (WBCs), (ii) the number of Sca-1 + c-kit + lineage -(SKL) cells in PB, and (iii) the number of circulating clonogenic colony-forming unit granulocyte/macrophage (CFU-GM) progenitors. In parallel, we evaluated by RQ-PCR changes in expression of genes involved in Nlrp3 inflammasome activation and by ELISA plasma level of C5 cleavage fragment C5a ELISA, and Nlrp3 inflammasome released Hmgb1, IL-1β, and IL-18 [12] .
We found that under steady-state conditions FB-KO mice have normal PB cell counts, red blood cell parameters, numbers of BM-residing and PB-circulating HSPCs, and numbers of clonogenic progenitors in BM compared with WT animals ( Supplementary Fig. 1 ). These animals were subsequently employed along with sex-matched and agematched syngeneic controls in our pharmacological mobilization induced by G-CSF or AMD3100 (Fig. 1a ). We noticed that these animals turned out to be poor stem cell mobilizers. The numbers of mobilized WBCs, SKL cells, and CFU-GM clonogenic progenitors were significantly lower in FB-KO mice than in control wild type (WT) mice. Moreover, we found that, in addition to HSPCs, FB-KO animals displayed decreased mobilization of other types of BM-residing stem/progenitor cells, including mesenchymal stroma cells (MSCs) and endothelial progenitor cells (EPCs), as well as a rare population of stem cells, very small embryonic like stem cells (VSELs) ( Supplementary Fig. 2 ).
This result shows that FB-mediated activation of the alternative pathway of ComC activation is important for optimal release of all types of BM-residing stem cells into PB.
In our recent paper as mentioned above, we provided evidence for a crucial role for Nlrp3 inflammasome activation in the pharmacological mobilization of HSPCs [10, 11] . Based on this evidence we analyzed the expression of genes involved in the inflammasome complex with respect to mRNA ( Fig. 1b) and protein (Fig. 1c) . We found a decrease in expression of mRNA for Nlrp3, ASC (Pycard), caspase 1, Hmgb1, IL-1β, and IL-18 in mRNA isolated from BM and PB MNCs from FB-KO mice. This defect in activation of the ComC and the Nlrp3 inflammasome was subsequently confirmed at the protein level, as we demonstrated a decrease in markers of Nlrp3 inflammasome activation circulating in PB, such as IL-1β, IL-18, and Hmgb1 [12] , in parallel with a decrease in level of the distal cleavage fragment of ComC activation C5a [11] .
During the mobilization process both the MBL and the alternative pathways of ComC activation lead to generation of the C5 cleavage fragments, the anaphylatoxins C5a and desArg C5a, as well as the soluble C5b-C9 membrane attack complex (MAC), which we found to promote egress of stem cells from BM into PB [13] . Our results show redundancy between the MBL and alternative pathways in this process (Fig. 2) . Based on this finding, it would be interesting to see whether simultaneous perturbation of the MBL and alternative pathways has a more profound effect than a single perturbation of one pathway or the other.
As we have recently demonstrated, adenosine triphosphate (ATP) that is released from innate immunity cells after administration of pro-mobilizing agents is an important trigger for Nlrp3 inflammasome activation [10, 11] . Several mediators released from innate immunity cells after Nlrp3 inflammasome activation, such as IL-1β, IL-18, and members of the family of danger-associated molecular pattern molecules (DAMPs), including highmobility group box 1 protein (Hmbg1) and S1000a9 protein, lead to activation of the ComC [10, 11] . This activation occurs via MASP-1, which also activates in parallel the coagulation cascade (CoaC) in the BM microenvironment and as reported CoaC supports mobilization process [14] .
The crucial role of the ComC in egress of HSPCs from BM has been demonstrated in C5-KO mice [2] , which do not generate the soluble mediators C5a, desArg C5, and C5b-C9 in the distal part of ComC activation. C5 and desArg C5a activated in the BM microenvironment potentiate Nlrp3 inflammasome activation and in PB provide a chemotactic gradient for granulocytes and monocytes to egress from BM. These innate immunity cells are enriched in proteolytic enzymes, including metalloproteinase 9 (MMP-9), and play an important role in permeabilization of the BM-PB endothelial barrier in BM sinusoids. As a consequence, HSPCs chemoatttacted by the S1P gradient in PB follow in the path of these cells to egress from the BM [15] . In the process of permeabilization of the endothelial barrier in BM, the anaphylatoxin C5a and its receptor C5aR, which is expressed on the surface of endothelial cells, also play a direct role [13] . Another C5 cleavage product, C5b, which leads to generation of MAC (C5b-C9), may additionally increase the chemotactic level of sphingosine-1 phosphate (S1P) for HSPCs in blood plasma [15] by triggering its release from erythrocytes and platelets.
What is also important is that, besides ATP, both C5a and C5bC9 are known activators of the Nlrp3 inflammasome in innate immunity cells [10] . In the present work we observed that, in contrast to WT animals, the Nlrp3 inflammasome is less efficiently activated in the BM of FB-KO animals in response to mobilizing drugs. This was expected, and accordingly we observed lower expression of mRNAs for Nlrp3 inflammasome components, as well as lower levels of IL-1β and IL-18 (which are markers of Nlrp3 inflammasome activation) released into PB in FB-KO mice.
In conclusion, we have demonstrated for the first time that the alternative pathway of ComC activation is involved in mobilization of hematopoietic and non-hematopoietic stem cells from BM into PB. We also demonstrated that this process occurs in an Nlrp3 inflammasome-mediated manner, as FB-KO mice activate this inflammasome components poorly. Moreover, since mobilization was not completely inhibited in FB-KO mice, as in our previous studies in MBL-KO animals, this result suggests a CSF on Nlrp3 inflammasome activation was evaluated at the mRNA level in PB. The expression of NLRP3, ASC (Pycard), CASP1, IL-1β, IL-18, HMGB1, S100a9, AIM2, GSDMD, NLRP1a, and NLRP1b mRNAs in PB after G-CSF and AMD3100 mobilization was measured by qRT-PCR. Sequences of primers and amplification parameters employed for these studies are shown in ref. [11] . Panel (c) The effect of G-CSF on Nlrp3 inflammasome activation was evaluated at the protein level by ELISA in PB plasma. To the Editor:
Autophagy is an evolutionarily conserved lysosomalmediated degradation process that facilitates the turnover of organelles and selected long-lived proteins. Aberrant autophagy contributes to therapeutic resistance and malignant progression by generating alternative sources of metabolic fuel to maintain cell survival under stress conditions, including those imposed by hypoxia, radiation, chemotherapy, and targeted agents [1] . The FDA approved antimalarial drug hydroxychloroquine (HCQ) is known to inhibit autophagy through the disruption of lysosomal function. Based on this aspect of its mechanism of action, tremendous efforts were undertaken to repurpose it for cancer therapy over the last decade. Although HCQ has been combined with an array of other anticancer regimens in clinical trials, these studies have predominantly reported modest clinical benefit characterized by partial responses and stable disease, but few sustained complete responses [2, 3] . Despite the initial subdued clinical results reported from these trials, there is maintained enthusiasm for autophagy inhibition as an anticancer approach for two overarching reasons. First, it remains unclear if the maximum tolerated dose of HCQ when used in combination with other anticancer agents is sufficient to completely inhibit autophagy in tumors. The pharmacodynamic (PD) studies conducted in support of most of these early phase HCQ combination trials were not powered to test this in a definitive manner. Residual autophagic activity may have been a factor that limited efficacy in these studies. Second, despite its prevalent use as an autophagy inhibitor, the reality is that HCQ is a very old drug that was not designed to inhibit autophagy. Its continued use for this purpose is driven by the lack of better alternatives. New autophagy inhibitors with increased potency and more favorable therapeutic indices are clearly needed to definitively determine the efficacy of this approach, but none have been tested in humans to date. We recently generated a series of novel dimeric compounds containing modified core elements of HCQ and the antischistosomal drug lucanthone with the goal of developing new lysosomal autophagy inhibitors with superior potency, tolerability, and anticancer efficacy [4, 5] . Initial preclinical studies identified ROC-325 as a lead agent for further investigation, as it demonstrated approximately tenfold greater potency than HCQ, and is an orally bioavailable compound. We selected acute myeloid leukemia (AML) as a priority malignancy for further investigation based on the high sensitivity of AML cells to ROC-325 in early screens and the frequent aberrations in the autophagy interactome in patients with myeloid neoplasms that we recently reported [6] . We first quantified the effects of ROC-325 on the hallmark features of autophagy inhibition in AML cells. Transmission electron microscopy analyses demonstrated that treatment of AML cells with ROC-325 triggered the accumulation of autophagosomes with undegraded cargo (Fig. 1a) . The majority of lysosomal proteases that control the autophagy-mediated degradation of proteins and organelles require a strict acidic pH microenvironment for their enzymatic activity. Based on this, lysosomal acidity is commonly used as a marker of autophagy status. We treated AML cells with ROC-325, and used LysoSensor Green to evaluate the effects of drug treatment on lysosomal pH. Confocal microscopy and FACS-based quantification of LysoSensor Green fluorescence both showed that ROC-325 stimulated lysosomal deacidification ( Supplementary  Fig. 1a, b , P < 0.01). Consistent with the disruption of autophagy by ROC-325 through impairment of lysosomal function, immunoblotting showed that drug treatment led to elevated levels of the microtubule-associated protein and autophagy marker LC3B along with accumulation of p62, whose turnover is specifically mediated by autophagy ( Fig. 1b ).
An important consideration in new agent development is improved selectivity for malignant cells, which may lead to better tolerability and reduced toxicity to normal cells. Treatment of normal human CD34+ bone marrow (BM) cells with ROC-325 in parallel with a panel of established AML cell lines demonstrated strong therapeutic selectivity as evidenced by a dose-dependent reduction in the viability of AML cells with limited effects on normal BM progenitors (Fig. 1c) . The diminished viability caused by ROC-325 treatment was associated with dose-dependent apoptosis ( Supplementary Fig. 2a-c) . Additional assays conducted with primary AML blasts from patients showed that ROC-325 displayed similar potency regardless of patient risk classification (N = 5 per group, Supplementary Fig. 3 ). This suggests that ROC-325 may have broad applications in AML therapy, and that patients that are predicted to have poor outcomes could potentially benefit from this novel agent.
We also conducted RNA sequencing and gene-level analyses to further investigate the PD effects of ROC-325 in AML cells. These studies demonstrated that the treatment of MV4-11 cells with ROC-325 (1 µM and 5 µM) altered the levels of autophagy-dependent degradation pathways while preserving protein synthesis through the upregulation of posttranslational ribosomal, methylation, and splicing components ( Supplementary Fig. 4a-c) .
The hypomethylating agent azacitidine (AZA) is frequently used in the management of patients with myelodysplastic syndromes (MDS) and AML [7, 8] . Recent reports have linked autophagy to AZA resistance, and have suggested that autophagy inhibition may be an effective strategy to augment the efficacy of AZA [9, 10] . To explore the potential benefit of autophagy inhibition as a new approach to increase the antileukemic activity of AZA, we first conducted a series of experiments to demonstrate that AZA treatment triggers autophagy in AML cells. Confocal microscopy analyses showed that AZA promoted the formation of LC3B punctae in AML cells ( Supplementary  Fig. 5a ), which is indicative of autophagy induction. Immunoblotting demonstrated that AZA stimulated the dose-dependent accumulation of LC3B with related reductions in the levels of the autophagy controlled protein p62, further supporting that AZA triggers autophagy (Supplementary Fig. 5b ). Combining ROC-325 with AZA antagonized its effects on p62, suggesting that this approach may increase its antileukemic activity ( Supplementary Fig. 5c ). To assess the impact of autophagy inhibition on AZA efficacy, we first tested the combination of ROC-325 and AZA in a panel of AML cell lines ( Fig. 2a ) and primary AML blasts ( Supplementary Fig. 6 ). In both cases, the combination yielded a significantly greater than additive benefit (P < 0.01). We next conducted a xenograft study to investigate the therapeutic potential of inhibiting autophagy with ROC-325 as a strategy to increase the benefit of AZA in vivo. MV4-11 cells were injected into the tail veins of NOD/SCID mice to establish a disseminated model of leukemia. Bone marrow engraftment efficiency was assessed by CD45 immunohistochemistry (IHC, Supplementary  Fig. 7) . Mice (N = 10 per group) were treated with vehicle control, 50 mg/kg ROC-325, 5 mg/kg AZA, or the combination of both agents. Animal weight was measured biweekly, and overall survival was used as an endpoint for the study. While both ROC-325 and AZA displayed significant anti-AML activity, combination treatment resulted in a significant further extension of overall survival compared with either single agent treatment (Fig. 2b) . Importantly, combination therapy was very well tolerated, and did not significantly affect animal weight (less than 5% mean transient reduction in body weight, Supplementary Fig. 8 ). Immunohistochemical PD analyses of BM and spleen specimens collected from animals in each group at study endpoint demonstrated that ROC-325 disrupted autophagy in vivo as shown by increased LC3B and p62 levels ( Fig. 2c; Supplementary Fig. 9 ). These data suggest that the induction of autophagy may represent a key mechanism that limits the efficacy of AZA, and that approaches to abrogate this aspect of AZA's mechanism of action could yield significant therapeutic benefit. Taken together, our findings demonstrate that the inhibition of autophagy is a novel approach to augment the benefit of AZA that warrants further investigation for the treatment of MDS/AML. Our results also support continued studies specifically focused on rigorously evaluating the safety, mechanism of action, and antileukemic activity of the novel orally available autophagy inhibitor ROC-325.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mice were treated with vehicle control, 50 mg/kg PO QD ROC-325, 5 mg/kg azacitidine IV Q3D, or both drugs. The survival benefit of each treatment was determined by Kaplan-Meier analysis. c ROC-325 inhibits autophagy in vivo. Bone marrow and spleen specimens were collected from mice in each treatment group at study endpoint, and levels of LC3B and p62 were measured by immunohistochemistry report the outcomes of the 20 SVT patients who were treated with PEG.
This study was an investigator-initiated phase 2 clinical trial that was performed in compliance with an Investigational New Drug Application and approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai and at all participating sites. It was supported by the National Cancer Institute, and PEG was generously supplied by Roche/Genentech.
Patients met 2008 World Health Organization (WHO) criteria for the diagnosis of ET/PV and were treated for up to 12 months with PEG with a primary objective of inducing PR/CR as defined by the European LeukemiaNet (ELN) [8] . Patients who achieved PR/CR could continue PEG therapy for a maximum of 4 years on study. Secondary objectives included evaluation of toxicity, safety, tolerability, and impact of PEG on key biomarkers of disease. Survival, incidence of myelodysplastic syndrome (MDS), myelofibrosis (MF), or leukemic transformation (LT) and incidence of major cardiovascular events during therapy with PEG were described.
PEG therapy was initiated at a dose of 45 µg subcutaneously weekly and the dose was titrated upwards each month by 45 µg to induce a CR, to a maximum dose of 180 µg. Clinical and laboratory assessments were conducted as per protocol every month for the first 6 months and then every 3 months afterwards.
For the SVT cohort, we estimated a CR + PR rate of 50% with an exact 95% confidence interval equal to the observed rate ±22%. Patients who discontinued therapy for any reason were considered to be failures in this intent to treat evaluation. Exact 95% confidence intervals were used to estimate the clinico-hematologic response rate in this SVT cohort.
Patients completed a comprehensi.ve assessment of their MPN-associated symptoms (Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)) [9] , an assessment of functionality and quality of life (EORTC QLQ-C30) and five exploratory questions to assess PEG-related side effects on a serial basis (baseline, 3, 6, 9, and 12 months). Changes over time were assessed by mixed models adjusting for age.
Myeloid neoplasm associated-gene mutations were detected by next generation sequencing using a targetedsequencing panel designed to capture 156 genes implicated in the pathogenesis of myeloid malignancies and described elsewhere [10] . Pathogenic significance of mutations was determined by previously published criteria [11] [12] [13] .
A total of 20 subjects with SVT [PV: 13 (65%); ET: 7 (35%)] were enrolled between February 2012 and December 2015. Baseline demographics of these 20 patients are shown in Table 1 . At time of enrollment, 18/20 (90%) patients were receiving anticoagulation/antiplatelet therapy including coumadin (n = 10), aspirin (n = 6), low molecular weight heparin (n = 2), and combination coumadin and aspirin (n = 1). The median number of weeks on treatment with PEG was 114.2 (11.0-209.9) and 16 (80%) patients received at least 48 weeks of therapy for the analysis of the primary efficacy endpoint. The median dose of PEG administered was 135 μg weekly (45.0-180.0), and treatment was continued to maintain hematologic response.
Mean MPN-SAF Total Symptom Score (TSS) was 15.6 amongst patients with SVT (SD 14.9; range 0-50), which was lower than the mean for non-SVT 111 study participants (n = 115, 19.5 [SD 18.4] ). Baseline quality of life was not significantly impaired, i.e. mean QLQ-C30 global health status/QOL was 71.7 (SD 19.9), which is similar to the non-SVT 111 study participants (71.6 [SD 20.1]) and a general After 12 months of therapy, the overall hematological response rate (ORR, CR + PR) was 70% (95% CI: 45.7-88.1%), with 3 (15%) CR, 11 (55%) PR, and 6 (30%) non-responses (NR). NR in 2 of these 6 patients was observed despite treatment with the maximal dose of 180 µg weekly. Fourteen of 20 patients had the opportunity to receive at least 36 months of treatment and the ORR at 36 months was 42.9% (95% CI: 18.9-70.4%). Reasons for NR (n = 8) at 36 months in the 14 patients who had completed sufficient time on study prior to sponsor study closure included lack of response despite maximal PEG dose of 180 µg weekly (n = 2), AE at 90, 135, or 180 µg weekly (n = 3), pregnancy (n = 1), and patient/physician withdrawal (n = 2). Of the 9 subjects with ultrasound studies performed at baseline and after 12 months of therapy, the median percent reduction in spleen length by imaging was 0.0% (range, -53.4-7.0%). None of the subjects developed MF, MDS, AML, or died during the study period. Each bar represents an individual patient and the colors denote best response status (red: CR, green: PR and blue: NR). The stars highlight patients who have significant change of VAF from baseline. These is a subset of patients for whom the 95% confidence interval of VAF (with respect to the depth of coverage of the mutation in corresponding sample) did not overlap between baseline and last time-points Treatment-emergent AEs, regardless of attribution, occurring in more than 10% of subjects were infrequent (data not shown). There were three bleeding events; grade 3 esophageal bleeding (n = 1), grade 1 gingival bleeding (n = 1), and grade 1 microscopic hematuria (n = 1). There were no recurrent episodes of SVT. One subject developed a grade 2 deep venous thrombosis (DVT) of the lower extremity 1 month following discontinuation of PEG therapy. Reasons for study treatment discontinuation included study closure (n = 7, 35%), AE (n = 4, 20%), non-response (n = 3, 15%), patient withdrawal (n = 2, 10%), treatment completion per protocol (n = 2, 10%), physician decision (n = 1, 5%), and pregnancy (n = 1, 5%).
Serial MPN-SAF questionnaire completion was achieved in 15 (75%) patients at 12 months. In a mixed model analysis, there were minimal MPN-specific symptom changes observed (however, some improvements in sad mood and sexuality improvement at 9 months were observed). SVT patients did experience statistically significant time-dependent worsening of PEG-related side effects such as flushing, injection site irritation, blurry vision, and visual changes (all p < 0.05). GHS/QOL stayed relatively stable over time for those patients who continued treatment (p = NS).
Seventeen patients had their mutational status assessed at baseline and all of these patients harbored JAK2V617F. The median JAK2V617F variant allele fraction at baseline was 15% (range 1-76%). TET2 and DNMT3A mutations were the most frequent co-occurring mutational events (Fig. 1a) . Among the 17 patients harboring JAK2V617F, the ORR (CR: 6, PR: 7) was 13/17 (76.5%) at 12 months. Among 14 patients with serial samples (Fig. 1b) , ELN defined molecular CR/PR was not achieved in any of the evaluable subjects. Four of the 20 patients had baseline karyotypic abnormalities and these abnormalities persisted after 12 and 24 months of treatment in the two patients with available follow-up analyses.
Based on blinded central expert histopathology assessment of bone marrow biopsy specimens from 17 patients (11 PV and 6 ET) with available and adequate materials at 12 months, two subjects attained a pathologic marrow CR. Clinical-hematologic responses in these two subjects were CR and PR.
SVT is a well described complication associated with ET and PV but optimal management remains poorly defined [6] . Current recommendations are that these high-risk patients be treated with myelosuppressive therapy (HU or PEG) [14] . However, HU has been reported to be ineffective in preventing recurrent SVT [4] . Also due to the relative youth of this patient population, there has been a reluctance to treat these patients with HU due to effects on fertility, teratogenicity and fear of possible leukemogenicity [6] . Recently, a phase 2 trial of the JAK1/2 inhibitor ruxolitinib in 9 ET/PV patients with SVT was reported to induce reduction in spleen volume but without any impact on degree of esopahageal varices [15] . In this prospective study, PEG therapy was well tolerated in patients with ET/ PV and a history of SVT and resulted in a clinicalhematologic ORR of 70% (15% CR and 55% PR) at 12 months of therapy.
PEG therapy for ET/PV patients with SVT had a favorable impact on certain MPN symptoms but was also associated with treatment emergent low-grade toxicities that can abrogate some of those benefits. Regardless, PEG did not clearly diminish QoL. SVT did not recur in any of the patients during a median follow-up of 2.2 years. This prospective study of PEG therapy in MPN patients with SVT demonstrates the feasibility and apparent efficacy of this therapy.
